See more : Sunway Real Estate Investment Trust (5176.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Pieris Pharmaceuticals, Inc. (PIRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pieris Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Goodyear Tire & Rubber Co. (GTPPP) Income Statement Analysis – Financial Results
- Medra Corporation (MDRA) Income Statement Analysis – Financial Results
- J. Front Retailing Co., Ltd. (JFROF) Income Statement Analysis – Financial Results
- Do Day Dream Public Company Limited (DDD.BK) Income Statement Analysis – Financial Results
- Coastal Corporation Limited (COASTCORP.NS) Income Statement Analysis – Financial Results
Pieris Pharmaceuticals, Inc. (PIRS)
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.81M | 25.90M | 31.42M | 29.32M | 46.28M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 9.88M | 11.38M |
| Cost of Revenue | 41.80M | 2.78M | 2.37M | 46.53M | 55.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.55M | 0.00 |
| Gross Profit | 1.01M | 23.12M | 29.05M | -17.21M | -8.72M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 12.43M | 11.38M |
| Gross Profit Ratio | 2.36% | 89.27% | 92.46% | -58.68% | -18.84% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 125.78% | 100.00% |
| Research & Development | 41.80M | 52.98M | 66.66M | 46.53M | 55.00M | 41.49M | 22.29M | 19.70M | 8.24M | 5.60M | 9.41M | 10.85M |
| General & Administrative | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 280.86K |
| SG&A | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.99M |
| Other Expenses | 13.91M | -8.17M | -3.69M | -3.66M | -26.00K | 1.80M | -2.10M | 119.50K | 10.91K | 3.00K | 6.31K | 0.00 |
| Operating Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Cost & Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Interest Income | 1.85M | 721.00K | 4.00K | 511.00K | 1.71M | 1.96M | 152.00K | 2.32K | 0.00 | 0.00 | 0.00 | 177.13K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95M | 2.32K | 184.65K | 2.65M | 493.94K | 0.00 |
| Depreciation & Amortization | 1.78M | 2.78M | 2.37M | 2.13M | 1.04M | 570.00K | 369.00K | 361.38K | 307.91K | 366.98K | 384.68K | 378.32K |
| EBITDA | -22.76M | -30.50M | -43.37M | -31.61M | -26.12M | -30.26M | -14.23M | -22.40M | -13.37M | -6.83M | 938.50K | -1.80M |
| EBITDA Ratio | -53.17% | -136.29% | -153.24% | -108.43% | -56.43% | -103.99% | -56.28% | -390.33% | -466.25% | -134.11% | 9.56% | -15.83% |
| Operating Income | -29.76M | -43.47M | -51.83M | -33.92M | -27.16M | -30.83M | -14.59M | -22.76M | -13.68M | -7.20M | 553.83K | -2.18M |
| Operating Income Ratio | -69.51% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.33% | -466.62% | -134.17% | 5.61% | -19.15% |
| Total Other Income/Expenses | 5.21M | 10.20M | 6.09M | -3.15M | 1.69M | 3.77M | -1.95M | 122.00K | -173.74K | -2.65M | -487.63K | -140.55K |
| Income Before Tax | -24.54M | -33.28M | -45.74M | -37.07M | -25.47M | -27.07M | -16.54M | -22.64M | -13.85M | -9.85M | 66.20K | -2.32M |
| Income Before Tax Ratio | -57.33% | -128.47% | -145.58% | -126.41% | -55.03% | -93.01% | -65.46% | -388.24% | -472.55% | -183.60% | 0.67% | -20.39% |
| Income Tax Expense | 0.00 | -2.02M | -2.37M | 164.00K | -1.71M | -312.00K | 1.10M | 161.97K | 203.87K | -18.00 | 487.63K | 22.00 |
| Net Income | -24.54M | -31.25M | -43.37M | -37.23M | -23.76M | -26.75M | -17.65M | -22.80M | -14.06M | -9.85M | 66.20K | -2.32M |
| Net Income Ratio | -57.33% | -120.66% | -138.03% | -126.97% | -51.33% | -91.93% | -69.82% | -391.02% | -479.50% | -183.59% | 0.67% | -20.39% |
| EPS | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| EPS Diluted | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| Weighted Avg Shares Out | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
| Weighted Avg Shares Out (Dil) | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
Earnings Preview: Pieris Pharmaceuticals
PIRS Stock: Over 5% Increase Pre-Market Explanation
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q4 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Misses Revenue Estimates
Pieris Pharmaceuticals: Q4 Earnings Insights
Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals's Earnings Outlook
PIRS Stock Price Increases Over 10% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports